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Discrete variables n (%)
Wilcoxon rank
sum p-value
mean rank of
total costs
Gender (male) 32 (37.2%) .526
NYHA III, IV 62 (72.1%) .472
Atrial fibrillation 19 (22.1%) .735
Carotid disease 4 (4.7%) .335
CAD 42 (48.8%) .140
Porcelain aoreta 5 (5.8%) .789
PVD 9 (10.5%) .239
Diabetes 21 (24.4%) .591
Pulmonary hypertension 14 (16.3%) .037 56.21 with
pht.
41.03 without
pht.
Mediastinal radiation 6 (7.0%) .919
Hyperlipidemia 29 (33.7%) .004 32.59 with hl.
49.05 without
hl.
COPD 14 (16.3%) .194
Renal failure 11 (12.8%) .781
Angina 18 (20.9%) .531
Previous MI 10 (11.6%) .215
Previous stroke-TIA 2 (2.3%) .626
Previous pacemaker 2 (2.3%) .071 12 with pm.
44.25 without
pm.
Previous CABG 25 (29.1%) .898
Previous valve surgery 4 (4.7%) .743
Previous PCI 17 (19.8%) .371
Year of intervention .091
2007-2009 43 (50.0%) 47.77
2010 20 (26.7%) 44.12
2011 23 (23.3%) 32.44
Continuous variables Mean (sd) Spearman rho’s
p-value
age (years) 81.8 (6.6) .989
log euroscore 25.6 (15.2) .559
AVA (cm2) 0.6 (0.15) .556
Mean grad (mmHg) 25.2 (17.0) .824
LVEF (%) 59.4 (12.7) .899
Conclusions: Total hospitalisation costs of TAVI amount to about €40,000. Main cost
driver is length of stay and valve cost. Costs decrease marginally over time. Most patient
characteristics are not significantly related to total hospitalisation costs.
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Background: For currently available percutaneous aortic valve prosthesis, device design
limitations and potential misplacement can lead to significant aortic regurgitation, which
can result in severe complications and have an impact on long-term survival. The Direct
Flow Medical (DFM) valve is repositionable and retrievable and has non metallic
inflatable cuff with a conformable design that results in better valve sealing. Compared to
the first generation, the new 18F prosthesis, has a smaller profile, increased radial force
and better handling. We report the first series of high risk patients who received the 18F
DFM transfemoral prosthesis for severe aortic stenosis. Aim of the study was to test the
safety and performance of the 18F Direct Flow Medical valve in high risk patients with
severe aortic stenosis.
Methods: In this prospective, multicenter, non-randomized clinical trial 100 symptomatic
patients with severe aortic stenosis and a logistic Euro-SCORE  20% will be enrolled.
The primary endpoint is freedom from all-cause mortality @ 30 days, secondary
endpoints were device success and safety according to the VARC criteria. Data are
monitored and events adjudicated by independent committees (DMC, CEC). All echo-
cardiograms and angiograms were assessed by an independent Core Laboratory.
Results: The study started in January 2012 in 5 centers in Europe. Five additional centers
will follow. As of May 2012, 25 patients have been enrolled (mean age 84.9 y, 76-95 yrs,
mean logistic Euro-Score 27.9%, mean STS 11%). The primary endpoint of freedom from
death at 30 days was achieved in all 25 patients. The valve was retrieved and reimplanted
in 4 patients. At present, 10 pts had core lab evaluation, revealing a mean transvalvular
gradient at 30 days of 11 mmHg. There was no aortic regurgitation in 8 pts and 2 had trace
aortic regurgitation.
Conclusions: The 18F DFM valve can be safely implanted, repositioned and, if
necessary retrieved in high risk patients with severe aortic stenosis. Preliminary results
suggest excellent hemodynamic performance with abolishing significant aortic regurgi-
tation. The results of the completed study will be available at TCT 2012.
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Background: The Direct Flow Medical (DFM) valve is repositionable and retrievable.
The non metallic inflatable and conformable design of the valve results in better sealing
but in less radial force which may have an impact on stability and valve function over
time. Aim of the study was to evaluate the 4-year clinical and echocardiographic outcome
of the first generation 22F-DFM percutaneous aortic valve.
Methods: From 2007 to 2008 31 symptomatic high-risk for surgery patients (mean age
824y) with severe aortic stenosis and a mean logistic EuroSCORE of 297% were the
subject of this analysis. Clinical, echocardiographic and hemodynamic follow-up were
obtained during 4 years.
Results: Survival rates were 81%, 69%, 60%, and 54% at 1,2,3,4 years, respectively. At
4 years, 83% of the patients, who survived, were in NYHA-class I, 17% in class II.
Echocardiography revealed a significant decrease of the mean gradient from baseline
(49.113.8 mmHg) to 30 days (19.16.8 mmHg, p  0.001), which remained stable
over 4 years. At 4-year follow-up, 80% of the patients had no aortic regurgitation, 20 %
had trace aortic regurgitation.
Conclusions: In this preliminary series, the first generation of the nonmetallic, reposi-
tionable and retrievable 22F-DFM valve was associated with acceptable clinical outcome
and stable hemodynamic performance with no aortic regurgitation in the majority of
patients.
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Background: Percutaneous transcatheter aortic valve implantation (TAVI) is associated
with favorable safety and efficacy outcomes in older patients at high risk for surgical AV
replacement. Health Related Quality of life (HRQoL) can be at least, if not more,
important than quantity of life in an elderly patient population, often frail, and with
multiple comorbidities. The Medtronic CoreValve ADVANCE is a prospective, multi-
center, 100% monitored study evaluating “real world” patients with severe aortic stenosis
treated with the CoreValve System (Medtronic, Minneapolis, MN). The HRQoL
measures collected in the ADVANCE study represents the largest, rigorously reported
cohort of HRQoL findings in the TAVI literature.
Methods: From March 2010 to July 2011, the ADVANCE study enrolled 1015 patients
at 44 experienced centers in Western Europe, Asia, and South America. HRQoL was
evaluated using the SF-12 and the EQ-5D, 2 general validated questionnaires. Results of
the measurements at baseline, 1 and 6 months are reported.
Results: Baseline clinical characteristics were: 50.6% female, age 81.16.4 y, log
EuroSCORE 19.212.4, 79.6% NYHA Class III/IV, 22.6% COPD, 21.4% prior CABG,
14.6% renal failure, and 12.9% cerebrovascular disease. Compared with baseline,
physical and mental summary score (PCS and MCS) measures and the EQ-5D index
significantly improved at 1 and 6 months.
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HRQoL Measure
Baseline
(BL) 1 Mo
p value
(1 Mo
vs BL)
6
Mos
p value
(6 Mos
vs BL)
EQ-5D Summary
Index
0.62 0.72 0.001 0.72 0.001
SF12-PCS† 32.82 39.00 0.001 39.74 0.001
SF12-MCS† 46.18 48.51 0.001 49.98 0.001
EQ-5D: from 0 [death] to 1 [perfect health].
†SF-12: from 0 to 100, with a higher score reflecting a better HRQoL
Conclusions: The ADVANCE study represents the largest, rigorously reported cohort of
HRQoL findings in the TAVI literature. All HRQoL measures significantly improved
compared with baseline at 1 and 6 months. An assessment of HRQoL by patient risk
profile according to EuroSCORE will be presented at the meeting.
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Background: The majority of patients have significant elevations in serum cardiac
biomarkers after transcatheter aortic valve replacement (TAVR) however the prognostic
significance of such elevations is unknown. Our aim was to assess incidence and
prognostic power of biomarker elevations after TAVR.
Methods: Clinical data of patients with aortic stenosis who were subjected to TAVR was
retrospectively analyzed. Myocardial necrosis markers cardiac troponin I (cTnI) and
creatine kinase (CK)-MB] were assessed during hospitalization.
Results: Among 150 TAVR patients, TA patients had significantly higher elevations both
for cTnI (13.814.0 vs. 2.55.8, p 0.001) and CK-MB (28.424.2 vs. 7.48.6, p
0.001) compared with TF patients. Biomarker elevations in TA patients did not have
any predictive power for patient outcome. However, by receiver operator curve analysis,
for TF patients, post-procedural CK-MB (2-fold increase) had high predictive power for
30-day mortality (area under the curve 0.85, p 0.001). Patients with high CK-MB had
higher rates of post-procedural kidney injury (22% vs. 6%, p0.026), in-hospital- (22%
vs. 0%, p 0.001), 30-day- (27% vs. 1.5%, p 0.001), and 1-year mortality (41% vs.
18%, p0.01).
Conclusions: Cardiac biomarker rise post-TAVR is common and more frequent among
TA access patients. A 2-fold increase (7 ng/ml) in CK-MB after TF-TAVR is a
surrogate for poor long-term outcome.
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Background: Transcatheter aortic valve replacement (TAVR) is the first major addition
to the treatment of valvular heart disease in more than a decade, and the number of
patients eligible for valve replacement is likely to increase significantly. As a conse-
quence, little is known about expectations within the cardiology community regarding the
utilization of this new therapy in clinical practice.
Methods: Four days after approval of the first TAVR device in November 2011 by the
U.S. Food and Drug Administration (FDA), we emailed an online questionnaire to 201
cardiologists involved in TAVR research and 461 recent members of the Society of
Cardiac Angiography and Interventions to evaluate anticipated TAVR referral patterns.
Follow-up reminders were sent during the next 4 weeks. Characteristics between
researchers and clinicians were compared using chi-square and t-tests.
Results: Of 205 responses received (31%), the majority of respondents were male (90%),
interventional cardiologists (86%), and working in academic practices (72%). Most
respondents (90%) planned to refer patients for TAVR immediately after the devices are
clinically available, and 70% stated that no more data were needed to confirm TAVR is
safe for clinical use. Although 75% of respondents anticipated referring less than
one-fourth of their patients with severe aortic stenosis for TAVR, 68% believed that
TAVR is equally efficacious as open-heart surgery, and 11% believed that moderate-
surgical risk patients should also be referred for TAVR. When comparing groups of
respondents, those involved in TAVR research studies were more conservative with
regard to anticipated referral patterns, as 81% would refer as soon as TAVR is clinically
available versus 98% of clinical cardiologists (p0.01).
Conclusions: These data provide insight into the expected utilization of TAVR after
FDA approval in November 2011. Despite remarkable enthusiasm and media attention for
TAVR over the past few years, our findings suggest cautious optimism among the U.S.
interventional cardiology community regarding the uptake of this new approach to
managing severe aortic stenosis.
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Background: The SAPIEN 3 transcatheter heart valve (Edwards Lifesciences Inc., USA)
incorporates an enhanced paravalvular sealing system, an active 3-dimensional coaxial
positioning catheter, and is compatible with an ultra-low profile 14 French expandable
sheath.
Methods: As a first-in-human trial the SAPIEN 3 transcatheter heart valve (Edwards
Lifesciences Inc., CA, USA) was implanted in 15 patients with symptomatic severe aortic
stenosis via femoral arterial access with a 14 French expandable sheath. Patients
underwent transthoracic echocardiography and multidetector computed tomography both
before and after valve implantation. Clinical and echocardiographic follow up was
obtained at 30 days. Outcomes were reported according to the Valve Academic Research
Consortium guidelines.
Results: All 15 device implants were successful. Aortic valve area increased from 0.7
0.2 cm2 to 1.5 0.2 cm2 (p 0.001) and mean trans-aortic gradient decreased from
42.2  10.3 mmHg to 11.9  5.3 mmHg (p  0.001). No patient had more than mild
paravalvular regurgitation. Hospital discharge occurred at 3 (2, 12) hospital days. At
30 days one patient had required a new pacemaker. There were no strokes, vascular
complications, transfusions, or deaths. All patients were in NYHA functional class I
or II at 30-day follow-up.
Conclusions: The ultra-low SAPIEN 3 transcatheter valve and delivery system may
facilitate fully percutaneous implantation in a broader range of patients with the potential
for more accurate positioning and less paravalvular regurgitation.
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Background: Balloon aortic valvuloplasty (BAV) is a palliative treatment for severe
aortic stenosis (AS). Restenosis after BAV can be resolved with another BAV or with
TAVI. We presented our experience with BAV and the results of RADAR-SLO study
where we evaluated the external beam radiation (EBRT) for prevention of restenosis.
Methods: Inclusion criteria for BAV were severe AS, increased operative risk, bridge to
surgical AVR/TAVI, urgent non-cardiac surgery. The severity of AS and LV function was
assessed with invasive and echocardiographic evaluation. In RADAR-SLO study we
randomized patients 2:1, the first group was treated with EBRT (total dose16Gy).
Results: 168 patients (age82.6y, LogEurosc22.1%) underwent BAV. After BAV we
observed an increase in AVA (0.59 to 0.70cm2, p0.05), a decrease in mean transval-
vular gradient (47.8 to 38mmHg, p0.05), without change of LV function (EF 53.3 to
54.9%, p0.75). The most common complications involved peripheral arterial accesses
(4.8%). BAV was performed in patients with CAD (N17) concomitant with PCI and in
patients with carcinoma (N7) that underwent major non-cardiac surgery. During 6
months follow up a restenosis of dilated valve occurred (restenosis rate 59%). Recurrence
of symptoms was resolved with another BAV (2 BAV N22, 3 BAV N3) or TAVI
(N22). During the follow up a trend towards better outcome was noted in the TAVI
patients. There was no impact of EBRT on restenosis and on survival rate (Fig.1).
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